Prolonged survival of vaccinated macaques after oral SIVmac239 challenge regardless of viremia control in the chronic phase

Vaccine

Volumn 26, Issue 51, 2008, Pages 6690-6698

  Suh, You S ^a   Park, Ki S ^b   Sauermann, Ulrike ^a   Kim, Kwang S ^b   Ahn, So S ^b   Franz, Monika ^a   Schulte, Reiner ^a   Wilfingseder, Doris ^c   Stoiber, Heribert ^c   Überla, Klaus ^d   Hunsmann, Gerhard ^a   Stahl Hennig, Christiane ^a   Sung, Young C ^b  

^a GERMAN PRIMATE CENTER   (Germany)

^b Pohang University of Science and Technology (POSTECH)   (South Korea)

^c Inst of Hygiene and Social Medicine   (Austria)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Adenovirus; DNA; Prolonged survival; Vaccination and SIVmac239

Indexed keywords

DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; PEPTIDE; PLACEBO; PLASMID DNA; POL PROTEIN; PROTEIN SVIF; PROTEIN VPX; RECOMBINANT ADENOVIRUS VECTOR VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; SIVMAC239; TRANSACTIVATOR PROTEIN; TYROSYLLYSYLTYROSYLMETHIONYLVALYL DEXTRO METHIONINE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS NUCLEOPROTEIN; VIRUS RNA; VPU PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS; MACACA; NONHUMAN; PLASMID; PLASMID GX10; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SURVIVAL TIME; T LYMPHOCYTE; VACCINATION; VIREMIA; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; GENE PRODUCTS, GAG; IMMUNITY, CELLULAR; MACACA MULATTA; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA; VIRAL LOAD; VIREMIA; VIRUS REPLICATION;

EID: 58149118098     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.055     Document Type: Article

References (46)

1. Daniel M.D., Kirchhoff F., Czajak S.C., Sehgal P.K., and Desrosiers R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the Nef gene. Science 258 (1992) 1938-1941
2. Horton H., Vogel T.U., Carter D.K., Vielhuber K., Fuller D.H., Shipley T., et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 76 (2002) 7187-7202
3. Lu S., Arthos J., Montefiori D.C., Yasutomi Y., Manson K., Mustafa F., et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J Virol 70 (1996) 3978-3991
4. Allen T.M., Mortara L., Mothe B.R., Liebl M., Jing P., Calore B., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 76 (2002) 4108-4112
5. Allen T.M., Jing P., Calore B., Horton H., O'Connor D.H., Hanke T., et al. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 76 (2002) 10507-10511
6. Evans D.T., Chen L.M., Gillis J., Lin K.C., Harty B., Mazzara G.P., et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 77 (2003) 2400-2409
7. Matano T., Kobayashi M., Igarashi H., Takeda A., Nakamura H., Kano M., et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 199 (2004) 1709-1718
8. Kawada M., Tsukamoto T., Yamamoto H., Takeda A., Igarashi H., Watkins D.I., et al. Long-term control of simian immunodeficiency virus replication with central memory CD4+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 81 (2007) 5202-5211
9. Vogel T.U., Reynolds M.R., Fuller D.H., Vielhuber K., Shipley T., Fuller J.T., et al. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 77 (2003) 13348-13360
10. Suh Y.S., Park K.S., Sauermann U., Franz M., Norley S., Wilfingseder D., et al. Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model. Vaccine 24 (2006) 1811-1820
11. Stahl-Hennig C., Suh Y.S., Park K.S., Sauermann U., Kim K.S., Ahn S., et al. Immunogenicity of a DNA prime and recombinant adenovirus boost regime significantly varies between rhesus macaques of Chinese and Indian origins. J Med Primatol 36 (2007) 195-205
12. Mofenson L.M. Interaction between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 421 June (1997) 1-9
13. Schacker T., Collier A.C., Hughes J., Shea T., and Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 125 (1996) 257-264
14. Baba T.W., Trichel A.M., An L., Liska V., Martin L.N., Murphey-Corb M., et al. Infection and AIDS in adult macaques after nontraumatic oral exposure to cell-free SIV. Science 272 (1996) 1486-1489
15. Stahl-Hennig C., Steinman R.M., Tenner-Racz K., Pope M., Stolte N., Matz-Rensing K., et al. Rapid infection of oral mucosal-associated lymphoid tissue with simian immunodeficiency virus. Science 285 (1999) 1261-1265
16. Spring M., Stahl-Hennig C., Stolte N., Bischofberger N., Heeney J., ten Haaft P., et al. Enhanced cellular immune response and reduced CD8(+) lymphocyte apoptosis in acutely SIV-infected Rhesus macaques after short-term antiretroviral treatment. Virology 279 (2001) 221-232
17. Stahl-Hennig C., Dittmer U., Nisslein T., Petry H., Jurkiewicz E., Fuchs D., et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol 77 (1996) 2969-2981
18. Tenner-Racz K., Stahl Hennig C., Uberla K., Stoiber H., Ignatius R., Heeney J., et al. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc Natl Acad Sci USA 101 (2004) 3017-3022
19. Khazand M., Peiberg C., Nagy M., and Sauermann U. Mhc-DQ-DRB haplotype analysis in the rhesus macaque: evidence for a number of different haplotypes displaying a low allelic polymorphism. Tissue Antigens 54 (1999) 615-624
20. Muhl T., Krawczak M., Ten Haaft P., Hunsmann G., and Sauermann U. MHC class I alleles influence set-point viral load and survival time in simian immunodeficiency virus-infected rhesus monkeys. J Immunol 169 (2002) 3438-3446
21. Sauermann U., Siddiqui R., Suh Y.S., Platzer M., Leuchte N., Meyer H., et al. Mhc class I haplotypes associated with survival time in simian immunodeficiency virus (SIV)-infected rhesus macaques. Genes Immun 9 (2008) 69-80
22. Ha S.J., Chang J., Song M.K., Suh Y.S., Jin H.T., Lee C.H., et al. Engineering N-glycosylation mutations in IL-12 enhances sustained cytotoxic T lymphocyte responses for DNA immunization. Nat Biotechnol 20 (2002) 381-386
23. Lee C.G., Choi S.Y., Park S.H., Park K.S., Ryu S.H., and Sung Y.C. The synthetic peptide Trp-Lys-Tyr-Met-Val-D-Met as a novel adjuvant for DNA vaccine. Vaccine 23 (2005) 4703-4710
24. Seth A., Ourmanov I., Schmitz J.E., Kuroda M.J., Lifton M.A., Nickerson C.E., et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74 (2000) 2502-2509
25. Lewis M.G., Bellah S., McKinnon K., Yalley-Ogunro J., Zack P.M., Elkins W.R., et al. Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses 10 (1994) 213-220
26. Murphey-Corb M., Martin L.N., Davison-Fairburn B., Montelaro R.C., Miller M., West M., et al. A formalin-inactivated whole SIV vaccine confers protection in macaques. Science 246 (1989) 1293-1297
27. Hel Z., Nacsa J., Tryniszewska E., Tsai W.P., Parks R.W., Montefiori D.C., et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. J Immunol 169 (2002) 4778-4787
28. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 (1998) 2103-2106
29. Giraldo-Vela J.P., Rudersdorf R., Chung C., Qi Y., Wallace L.T., Bimber B., et al. The major histocompatibility complex class II alleles Mamu-DRB1*1003 and -DRB1*0306 are enriched in a cohort of simian immunodeficiency virus-infected rhesus macaque elite controllers. J Virol 82 (2008) 859-870
30. Yant L.J., Friedrich T.C., Johnson R.C., May G.E., Maness N.J., Enz A.M., et al. The high-frequency major histocompatibility complex class I allele Mamu-B*17 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 80 (2006) 5074-5077
31. Wojcechowskyj J.A., Yant L.J., Wiseman R.W., O'Connor S.L., and O'Connor D.H. Control of simian immunodeficiency virus SIVmac239 is not predicted by inheritance of Mamu-B*17-containing haplotypes. J Virol 81 (2007) 406-410
32. Zhao J., Pinczewski J., Gomez-Roman V.R., Venzon D., Kalyanaraman V.S., Markham P.D., et al. Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 77 (2003) 8354-8365
33. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 (2004) 2212-2221
34. Casimiro D.R., Wang F., Schleif W.A., Liang X., Zhang Z.Q., Tobery T.W., et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79 (2005) 15547-15555
35. Edwards B.H., Bansal A., Sabbaj S., Bakari J., Mulligan M.J., and Goepfert P.A. Magnitude of functional CD8+ T-cell responses to the gag protein of human immunodeficiency virus type 1 correlates inversely with viral load in plasma. J Virol 76 (2002) 2298-2305
36. Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science (New York, NY) 1997;278:1447-50.
37. Kalams S.A., Buchbinder S.P., Rosenberg E.S., Billingsley J.M., Colbert D.S., Jones N.G., et al. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 73 (1999) 6715-6720
38. Malkevitch N.V., Patterson L.J., Aldrich M.K., Wu Y., Venzon D., Florese R.H., et al. Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology 353 (2006) 83-98
39. Capitanio J.P., Abel K., Mendoza S.P., Blozis S.A., McChesney M.B., Cole S.W., et al. Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease. Brain Behav Immun 22 (2008) 676-689
40. Shivraj S.O., Chattopadhya D., Grover G., Kumar A., and Baveja U.K. Role of HCV coinfection towards disease progression and survival in HIV-1 infected children: a follow-up study of 10 years. J Trop Pediatr 52 (2006) 206-211
41. Seman A.L., Pewen W.F., Fresh L.F., Martin L.N., and Murphey-Corb M. The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol 81 (2000) 2441-2449
42. Mattapallil J.J., Douek D.C., Buckler-White A., Montefiori D., Letvin N.L., Nabel G.J., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203 (2006) 1533-1541
43. Smith S.M. HIV CTL escape: at what cost?. Retrovirology 1 (2004) 8
44. Martin M.P., Gao X., Lee J.H., Nelson G.W., Detels R., Goedert J.J., et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 31 (2002) 429-434
45. Alter G., Malenfant J.M., Delabre R.M., Burgett N.C., Yu X.G., Lichterfeld M., et al. Increased natural killer cell activity in viremic HIV-1 infection. J Immunol 173 (2004) 5305-5311
46. Cohen J Science. AIDS research. Promising AIDS vaccine's failure leaves field reeling. Science 2007;318:28-9.